

# Patient Benefit Investigation Form

Phone: 1-855-495-9200

Fax: 1-877-309-7514

Email: reimbursement@blueearthdx.com

## REQUESTED SERVICE

- Benefit investigation only     Prior authorization assistance  
 Appeal/denial assistance

## PATIENT AUTHORIZATION TO SHARE HEALTH AND USE INFORMATION

Printed name \_\_\_\_\_  
 \_\_\_\_\_

### The following information should be filled out by your healthcare provider

HCPCS:  A9588     Other: \_\_\_\_\_

CPT<sup>®</sup> codes:  78812     78813     78815     78816

Other: \_\_\_\_\_

Diagnosis code C61     Yes     No

Diagnosis code Z85.46     Yes     No

Diagnosis code R97.21     Yes     No

Other diagnosis codes:  
 \_\_\_\_\_

Suspicion of recurrent disease after previously treated prostate cancer:  Yes     No

Suspected recurrence based on:

Elevated PSA levels: \_\_\_\_\_

Prior studies/treatment: \_\_\_\_\_

Radical prostatectomy     Yes     No    Date: \_\_\_\_\_

Radiation therapy to prostate     Yes     No    Date: \_\_\_\_\_

Other treatments: \_\_\_\_\_ Date: \_\_\_\_\_

Previous imaging studies:  CT     MRI     Bone scan

Other: \_\_\_\_\_

I verify that the patient and physician information contained in this enrollment form is complete and accurate to the best of my knowledge and that I have prescribed Axumin based on my professional, independent judgment of medical necessity and it will be used as directed. I certify that I have received the appropriate permission from the patient and met any other applicable requirements imposed under the Health Insurance Portability and Accountability Act of 1996 and/or state law needed to release the above information to Blue Earth Diagnostics and its agents for the purposes of verifying the patient's insurance coverage, on my patient's behalf, and providing information on prior authorization and/or appeals for denials of claims. I authorize the Axumin Reimbursement Support Helpline Program to perform a preliminary assessment of insurance and benefit investigation for the above-named patient, and I further authorize and request that the Program provide to me information regarding Axumin for my reference in completing documentation as may be required by the patient's health plan. I further authorize Axumin Reimbursement Support to submit, at my request, information provided by me on this form and documentation completed by me to applicable health plans.

Prescriber signature required (no stamps)    \_\_\_\_\_    Date \_\_\_\_\_

## PATIENT DEMOGRAPHIC INFORMATION

First name \_\_\_\_\_ MI \_\_\_\_\_

Last name \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ ZIP \_\_\_\_\_

Mobile phone # \_\_\_\_\_ Last 4 of SSN \_\_\_\_\_

Email \_\_\_\_\_ DOB \_\_\_\_\_

Primary insurance \_\_\_\_\_

Policy holder \_\_\_\_\_ Group # \_\_\_\_\_

Policy # \_\_\_\_\_ Phone # \_\_\_\_\_

Secondary insurance \_\_\_\_\_

Policy holder \_\_\_\_\_ Group # \_\_\_\_\_

Policy # \_\_\_\_\_ Phone # \_\_\_\_\_



NOTE: Copy of insurance card(s) acceptable in lieu of completing insurance information above. Please include both sides of card.

## REFERRING PHYSICIAN INFORMATION

Physician name \_\_\_\_\_

Physician specialty \_\_\_\_\_

Practice name \_\_\_\_\_

Practice address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ ZIP \_\_\_\_\_

TIN # \_\_\_\_\_ Medicare PTAN \_\_\_\_\_

NPI # \_\_\_\_\_

Contact person \_\_\_\_\_

Contact phone # \_\_\_\_\_ Fax # \_\_\_\_\_

Contact email \_\_\_\_\_

## SITE OF AXUMIN PET/CT SCAN

Hospital outpatient     Physician practice

Independent diagnostic testing facility

Other: \_\_\_\_\_

Name of facility \_\_\_\_\_

TIN # \_\_\_\_\_ Medicare PTAN \_\_\_\_\_

NPI # \_\_\_\_\_

Facility contact name \_\_\_\_\_

Facility contact phone # \_\_\_\_\_

Facility contact email \_\_\_\_\_

# Patient Benefit Investigation Form

**AXUMIN**<sup>®</sup>  
Fluciclovine F 18 Injection

## PATIENT AUTHORIZATION TO SHARE HEALTH INFORMATION

I understand that I must authorize the use and disclosure of certain personal health information (“PHI”) before I can receive assistance through the Axumin Reimbursement Support Helpline Program (the “Program”). I hereby authorize my healthcare providers, pharmacies, and health plan(s) to disclose my PHI related to my medical condition and treatment, and all information provided on this patient enrollment form, to Blue Earth Diagnostics, the manufacturer of Axumin, and to its agents and the administrator of the Program (collectively, the “Recipients”). I further authorize the Recipients to use and disclose my PHI for the purposes of establishing my eligibility for benefits from my health plan or other programs, providing educational and reimbursement support, communicating with my healthcare providers and health plan(s), and for Blue Earth Diagnostics’ internal business purposes, including quality control and compliance. I understand that signing this authorization is voluntary and that if I were to refuse to sign, that would not affect my eligibility for health plan benefits or ability to obtain treatment by my healthcare providers. I also understand, however, that if I refuse to sign, I will not have access to the services offered by the Program. I also understand that if I sign this authorization, I can cancel it at any time by notifying Blue Earth Diagnostics in writing at [reimbursement@blueearthdx.com](mailto:reimbursement@blueearthdx.com). Upon receiving my notice of cancellation, Blue Earth Diagnostics would stop using this authorization to access, use, or disclose my PHI, and would notify my healthcare providers and health plan(s) of the cancellation, but the cancellation would not invalidate reliance on the authorization prior to its cancellation. I understand that once disclosures of my PHI pursuant to this authorization have occurred, that PHI may no longer be protected by certain federal or state privacy laws and therefore could potentially be re-disclosed to others.

This authorization will expire 5 years after the date it is signed below or at such earlier time as may be required by applicable state law. I have read this authorization or have had it explained to me. I understand that I will receive a copy of this authorization after I sign it.

Patient signature

Date

Abbreviations: CPT, current procedural terminology; HCPCS, Healthcare Common Procedure Coding System.

CPT<sup>®</sup> is a registered trademark of the American Medical Association. CPT Copyright 2021 American Medical Association. All rights reserved.

## INDICATION

Axumin<sup>®</sup> (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

## IMPORTANT SAFETY INFORMATION

- Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended.
- Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.
- Axumin use contributes to a patient’s overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers.
- Adverse reactions were reported in ≤1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.

**To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

**Please see accompanying full Axumin Prescribing Information, also available at [www.axumin.com](http://www.axumin.com).**